Development of a screening assay to evaluate the potential of drugs to cause immune-mediated hypersensitivity reactions

References

• Adams, A. E., Bobrove, A. M., and Gilliam, A. C. 2010. Statins and “chameleon-like” cutaneous eruptions: Simvastatin-induced acral cutaneous vesiculobullous and pustular eruption in a 70-year-old man. J. Cutan. Med. Surg. 14:207–211
   PubMed Web of Science ®Google Scholar
• Adkinson, N. F. Jr., Essayan, D., Gruchalla, R., et al. 2002. Task force report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. J. Allergy Clin. Immunol. 109:S461–S478
   PubMed Web of Science ®Google Scholar
• Basset, H. M., and Robins, A. H. 1980. First-pass effect and intrinsic clearance of propranolol and pindolol in the isolated perfused rat liver. S. Afr. Med. J. 58:971–973
   PubMedGoogle Scholar
• Beghi, E., and Shorvon, S. 2011. Anti-epileptic drugs and the immune system. Epilepsia. 52:40–44
   PubMedGoogle Scholar
• Berg, P. A., and Daniel, P. T. 1987. Co-trimoxazole-induced hepatic injury - an analysis of cases with hypersensitivity-like reactions. Infection. 15:S259–S264
   PubMedGoogle Scholar
• Burkhart, C., von Greyerz, S., Depta, J. P., et al. 2001. Influence of reduced glutathione on the proliferative response of sulfamethoxa-zole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. Br. J. Pharma-col. 132:623–630
   PubMed Web of Science ®Google Scholar
• Cheng, L., Stewart, B. J., You, Q., et al. 2008. Covalent binding of the nitroso metabolite of sulfamethoxazole is important in induction of drug-specific T-cell responses in vivo. Mol. Pharmacol. 73:1769–1775
   PubMedGoogle Scholar
• Chung, W. H., Hung, S. I., Hong, H. S., et al. 2004. Medical genetics: A marker for Stevens-Johnson syndrome. Nature. 428:486
   PubMed Web of Science ®Google Scholar
• Correia, O., Delgado, L., Ramos, J. P., et al. 1993. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involve-ment. Arch. Dermatol. 129:466–468
   PubMedGoogle Scholar
• Cribb, A. E., Lee, B. L., Trepanier, L. A., and Spielberg, S. P. 1996. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: Clinical syndromes and pathogenesis. Adverse Drug React. Toxicol. Rev. 15:9–50
   PubMed Web of Science ®Google Scholar
• Dieckhaus, C. M., Fernandez-Metzler, C. L., King, R., et al. 2005. Negative ion tandem mass spectrometry for the detection of glutathione conjugates. Chem. Res. Toxicol. 18:630–638
   PubMed Web of Science ®Google Scholar
• Dimasi, J. A. 2001. Risks in new drug development: Approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69:297–307
   PubMed Web of Science ®Google Scholar
• Garcia, M. J., Reinoso, R. F., Sanchez, N. A., and Prous, J. R. 2003. Clinical pharmacokinetics of statins. Meth. Find Exp. Clin. Pharmacol. 25:457–481
   PubMed Web of Science ®Google Scholar
• Goebel, C., Griem, P., Sachs, B., et al. 1996. The popliteal lymph node assay in mice: Screening of drugs and other chemicals for immunotoxic hazard. Inflamm. Res. 45:S85–S90
   Google Scholar
• Harr, T., and French, L. E. 2010. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet. J. Rare Dis. 5:39--49
   PubMed Web of Science ®Google Scholar
• Kumari, R., Timshina, D. K., and Thappa, D. M. 2011. Drug hypersensitivity syndrome. Indian J. Dermatol. Venereol. Leprol. 77:7–15
   PubMed Web of Science ®Google Scholar
• Ludwig, I. S., Kwast, L. M., Fiechter, D., and Pieters, R. H. 2010. An in vivo tiered approach to test immunosensitization by low molecular weight compounds. Meth. Mol. Biol. 598:27–37
   PubMedGoogle Scholar
• McCormack, M., Alfirevic, A., Bourgeois, S., et al. 2011. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. New Engl. J. Med. 364:1134–1143
   PubMed Web of Science ®Google Scholar
• Miyauchi, H., Hosokawa, H., Akaeda, T., et al. 1991. T-Cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T-cells. Arch. Dermatol. 127:851–855
   PubMedGoogle Scholar
• Olson, H., Betton, G., Robinson, D., et al. 2000. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32:56–67
   PubMed Web of Science ®Google Scholar
• Ozeki, T., Mushiroda, T., Yowang, A., et al. 2011. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20:1034–1041
   PubMed Web of Science ®Google Scholar
• Park, B. K., Boobis, A., Clarke, S., et al. 2011. Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discov. 10:292–306
   PubMed Web of Science ®Google Scholar
• Rendic, S. 2002. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab. Rev. 34:83–448
   PubMed Web of Science ®Google Scholar
• Rieder, M. J., Uetrecht, J., Shear, N. H., et al. 1989. Diagnosis of sulfonamide hypersensitivity reactions by in vitro ‘rechallenge’ with hydroxylamine metabolites. Ann. Intern. Med. 110:286–289
   PubMed Web of Science ®Google Scholar
• Ruger, R. D., Simon, J. C., and Treudler, R. 2011. Subacute-cutaneous lupus erythematosus induced by Simvastatin. J. Dtsch. Dermatol. Ges. 9:54–55
   PubMed Web of Science ®Google Scholar
• Rzany, B., Correia, O., Kelly, J. P., et al. 1999. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: A case-control study. Study Group of the International Case Control Study on Severe Cuta-neous Adverse Reactions. Lancet. 353:2190–2194
   PubMed Web of Science ®Google Scholar
• Schnyder, B., Burkhart, C., Schnyder-Frutig, K., et al. 2000. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T-cells from allergic individuals. J. Immunol. 164:6647–6654
   PubMed Web of Science ®Google Scholar
• Soglia, J. R., Contillo, L. G., Kalgutkar, A. S., et al. 2006. A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid chromatography-tandem mass spectrometry and novel quarternary ammonium glutathione analogues. Chem. Res. Toxicol. 19:480–490
   PubMed Web of Science ®Google Scholar
• Uetrecht, J. 2003. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov. Today. 8:832–837
   PubMed Web of Science ®Google Scholar
• Uetrecht, J. 2007. Idiosyncratic drug reactions: Current understanding. Annu. Rev. Pharmacol. Toxicol. 47:513–539
   PubMed Web of Science ®Google Scholar
• Weaver, J. L., Chapdelaine, J. M., Descotes, J., et al. 2005. Evaluation of a lymph node proliferation assay for its ability to detect pharmaceuticals with potential to cause immune-mediated drug reactions. J. Immunotoxicol. 2:11–20
   PubMedGoogle Scholar
• Yan, Z., Maher, N., Torres, R., and Huebert, N. 2007. Use of a trapping agent for simultaneous capturing and high-throughput screening of both “soft” and “hard” reactive metabolites. Anal. Chem. 79:4206–4214
   PubMed Web of Science ®Google Scholar